jc idarucizumab
TRANSCRIPT
-
7/24/2019 JC Idarucizumab
1/31
Journal Club
Idarucizumab for Dabigatran Reversal
.
533150189-6 6
-
7/24/2019 JC Idarucizumab
2/31
REVERSE-AD
Reversal Effects of Idarucizumab on
Active Dabigatran
Impact factor = 55.873 (2014)
-
7/24/2019 JC Idarucizumab
3/31
-
7/24/2019 JC Idarucizumab
4/31
Outline
Background and Rationale
Objective
Methods
Results
Conclusion
Critical Appraisal Skills Programme (CASP)
-
7/24/2019 JC Idarucizumab
5/31
CRITICAL APPRAISAL SKILLS
PROGRAMME
Checklist for cohort studies
Are the results of the study valid? What are the results?
Will the results help locally?
-
7/24/2019 JC Idarucizumab
6/31
(A)1. Did the study address a clearly
focused issue?
Yes, the study clearly focuses on beneficial
effect as the efficacy and safety of
idarucizumab as reversal agent fordabigatran.
-
7/24/2019 JC Idarucizumab
7/31
Background and Rationale
Specific reversal agents for non-vitamin K
antagonists oral anticoagulants are lacking.
Idarucizumab is developed to reverse its
effects.
-
7/24/2019 JC Idarucizumab
8/31
Objective
Demonstrate efficacy of idarucizumab for reversal of
anticoagulant effect of Dabigatran
Assessment of bleeding and safety of idarucizumab
-
7/24/2019 JC Idarucizumab
9/31
(A) 2. Was the cohort recruited in an
acceptable way?
Yes
Cohort is a representative of defined
population.However, this study only included the
bleeding patients whose dilute thrombin
time and ecarin clotting time above the
upper limit of normal range.
-
7/24/2019 JC Idarucizumab
10/31
Methods
Multicenter study (>400 centers in 38
countries)
Open label, uncontrolled, prospective cohort
study
Interim study
Clinical study Phase 3
-
7/24/2019 JC Idarucizumab
11/31
Study Eligibility
Inclusion criteria
Adults, 18 years or older, taking dabigatran
Presented in Emergency department
Exclusion criteria
Patients whose have dTT and ECT above
upper limit of normal range.
-
7/24/2019 JC Idarucizumab
12/31
-
7/24/2019 JC Idarucizumab
13/31
Study Design
Group APatients who exhibit sign and
symptoms of uncontrolled or
life-threatening bleeding
Group BPatients who require emergency
surgery /other medical procedure
necessitating rapid reversal of
anticoagulant effect of dabigatran
before surgery/ procedure
Patients received 5g of IV idarucizumab as
two 50ml bolus infusions, administered15 minutes apart
-
7/24/2019 JC Idarucizumab
14/31
3. Was the exposure accurately
measured to minimize bias?
Yes
Efficacy of Idarucizumab is measured using
dilute thrombin time and ecarin clotting
time which is an objective measures.
All the subjects classified into eachexposure group using the same procedure.
-
7/24/2019 JC Idarucizumab
15/31
Study Endpoints
Primary endpoint- maximum percentage of
reversal of anticoagulant effect of dabigatran
(measured by dilute thrombin time or ecarin
clotting time)
Secondary endpoint-
Proportion of patients who had complete
normalization of the dilute thrombin time or
ecarin clotting time in the first 4 hours and thereduction in the concentration of unbound
dabigatranClinical outcomes as assessed by the physicians
-
7/24/2019 JC Idarucizumab
16/31
4. Was the outcome accurately
measured to minimize bias?
Yes,
Similar measurement methods in the
different groups.Use of ECT and dTT comes from results of
previous study (Glund et al.)
No blinding is done.
-
7/24/2019 JC Idarucizumab
17/31
Statistical Analysis
Descriptive statistics with Confidence
interval or percentile as appropriate
-
7/24/2019 JC Idarucizumab
18/31
5. (a) Have the authors identified all important
confounding factors?
(b) Have they taken account of the confoundingfactors in the design and/or analysis?
Cant tell
No confounding factor is noted inthis study.
-
7/24/2019 JC Idarucizumab
19/31
6. Was the follow up of subjects
complete and long enough?
Yes,
After receiving Idarucizumab,patients were followed until death or
for at least 1 month.
-
7/24/2019 JC Idarucizumab
20/31
(B) 7. What are the results of this study?
8. How precise are the results?
Median maximum percentage reversal in the
patients in group A and B were 100%( 95%CI 100 to 100), evident after 1stinfusion.
-
7/24/2019 JC Idarucizumab
21/31
Results
-
7/24/2019 JC Idarucizumab
22/31
Results
-
7/24/2019 JC Idarucizumab
23/31
Results
-
7/24/2019 JC Idarucizumab
24/31
-
7/24/2019 JC Idarucizumab
25/31
Results
-
7/24/2019 JC Idarucizumab
26/31
Results
-
7/24/2019 JC Idarucizumab
27/31
-
7/24/2019 JC Idarucizumab
28/31
9. Do you believe the results?
Cant tell,Number of patients is too small (total of 90 patients)
More number of patients are needed in the study.
(C) 10. Can the results be applied to the localpopulation?
Yes,
It would be unethical to use RCT in these
patients.The results can be generalized.
-
7/24/2019 JC Idarucizumab
29/31
11. Do the results of this study fit with
other available evidence?
Yes,
It is consistent with the previous studyperformed in healthy volunteers.
12. What are the implications of this study for
practice?
This interim study provides the result tosupport that idarucizumab can be used to
reverse the anticoagulant effects ofdabigatran.
-
7/24/2019 JC Idarucizumab
30/31
Conclusion
Idarucizumab rapidly and completely
reversed the anticoagulant activity of
dabigatran in 88 to 98% of patients.No safety concerns
-
7/24/2019 JC Idarucizumab
31/31
Reference
1. Pollack CV, Reilly PA, Eikelboom J, Glund S,
Verhamme P, Bernstein R, et al. Idarucizumab
for Dabigatran Reversal. N Engl J Med2015;373:511-20
2. Critical Apprasial Skills Programme, cohortstudy checklist (2013)